The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure

Heart, Lung, and Circulation, 05/18/2012

This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.


  • In this randomised, double blind, placebo controlled trial.
  • People with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40mg (4ml) of nebulised frusemide or 4ml of normal saline.
  • Following inhalation of the study medication, subjects’ pulmonary pressures were recorded every 15min for 1h.


  • There were no significant changes in the weighted average time course data of the subjects (n=32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups.
  • Weighted average pulmonary capillary wedge pressure after 60min in the frusemide group was 22.5 (SD 6.5) mmHg (n=14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n=18), p=0.55.
  • The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186ml IQR 137.8–260.8) compared to the placebo group (76ml IQR 39.0–148.0) p=0.02.

Print Article Summary Cat 2 CME Report